These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22219068)

  • 1. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.
    Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J
    Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
    Deroose JP; Burger JW; van Geel AN; den Bakker MA; de Jong JS; Eggermont AM; Verhoef C
    Ann Surg Oncol; 2011 Feb; 18(2):321-7. PubMed ID: 21049306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
    Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
    J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Limb perfusion in soft tissue sarcomas: twenty years of experience].
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
    Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
    Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
    J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.
    Grabellus F; Kraft C; Sheu SY; Ebeling P; Bauer S; Lendemans S; Schmid KW; Taeger G
    Ann Surg Oncol; 2009 Mar; 16(3):676-86. PubMed ID: 19130134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
    Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
    Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
    Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
    Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.
    Schwindenhammer B; Podleska LE; Kutritz A; Bauer S; Sheu SY; Taeger G; Schmid KW; Grabellus F
    World J Surg Oncol; 2013 Aug; 11(1):185. PubMed ID: 23938063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.